Business Wire

Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting

Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors AU-007’s unique ...

The Most Haunting Music in ‘The Odyssey’ Has Ancient Roots

Ludwig Göransson’s soundtrack for Christopher Nolan’s film resurrects an ancient instrument, the aulos, to evoke the ...
Yahoo

Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma

Add Yahoo as a preferred source to see more of our stories on Google. Aulos Bioscience plans to progress its lead IL-2-targeting asset Aulos Bioscience's cancer therapy, imneskibart, could enter a ...
Business Wire

Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer ...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced ...
Yahoo Finance

Aulos Bioscience doses first patient in avelumab lung cancer trial

US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck KgaA ...
Morningstar

Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting

Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting 33% ORR and 67% disease control observed with ...
Yahoo Finance

Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual ...

LARKSPUR, Calif., October 03, 2025--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody ...
MarketWatch

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting

Aulos(TM) Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data ...
FierceBiotech

Aulos raises $40M to unlock the anti-cancer power of IL-2

ATP and Biolojic Design have teamed up to create IL-2-focused cancer biotech Aulos Bioscience. The startup begins life with IL-2-binding monoclonal antibodies designed by Biolojic Design and a $40 ...
MarketWatch

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of continued ...
RTBF

A la découverte de l’aulos, instrument emblématique de la Grèce antique

Aulos, l’instrument antique utilisé par toutes les couches sociales de la population Un tuyau à anche simple au double, en roseau en bois ou en métal, percé de plusieurs trous – le nombre variant ...